Investigational drug · Phase 2
HX301
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HX301"
First trial start
2025
Jan 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HX301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HX301" as an intervention, largest first.
Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
NCT06703255 · 72 participants (planned) · Start Jan 8, 2025 · Primary completion Dec 31, 2026
Drug: HX301+/Temozolomide · For: Glioma
Sites: Beijing, China
- Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic MalignanciesStatus unknown
Traws Pharma, Inc.Industry
NCT05705505 · 60 participants (planned) · Start Mar 29, 2023 · Primary completion Jan 2026
Drug: Narazaciclib; Letrozole 2.5mg · For: Endometrioid Endometrial Cancer
Sites: Tucson, Arizona; Minneapolis, Minnesota; Mineola, New York · 8 sites in all
- Study of ON 123300 in Patients With Advanced CancerStatus unknown
Traws Pharma, Inc.Industry
NCT04739293 · 36 participants (planned) · Start May 13, 2021 · Primary completion Oct 2024
Drug: ON123300 · For: Solid Tumors, Adult
Sites: Grand Rapids, Michigan; Greenville, South Carolina; Dallas, Texas
Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
NCT05731934 · 20 participants · Start Sep 15, 2020 · Primary completion Jan 12, 2024
Drug: HX301 · For: Advanced Solid Tumors
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.
Yang T, Ke H, Liu J, et al. · Sci Rep 2024
Also in development for Glioma
- SafusidenibDS-1001b, AB-218Phase 34 trials
Nuvation Bio Inc. · Oligodendroglioma, Glioma, IDH1-mutant Glioma
- APG-157Phase 33 trials
Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- silevertinibBDTX-1535Phase 22 trials
Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM
- VAL-083Phase 21 trial
Kintara Therapeutics, Inc. · Glioma, Glioblastoma, Glioblastoma Multiforme
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.